Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,Eculizumab Biosimilar ,Oncology At Samsung Medical Center ,Department Of Internal Medicine Division Hematology ,Jun Ho Jang ,Internal Medicine Division ,Samsung Medical Center ,Soo Min Lim ,Non Asian Patients ,Paroxysmal Nocturnal Hemoglobinuria ,Subgroup Analysis ,Global Phase ,Controlled Trial ,Eculizumab ,Biosimilar ,Sb12 ,